AAV-Based Gene Therapy: Opportunities, Risks, and Scale-Up Strategies

Area of Science:

• Gene Therapy
• Viral Vectors
• Biotechnology

Background:

• Adeno-associated virus (AAV)-based gene therapy is a rapidly advancing field for treating diverse diseases.
• Despite its potential, AAV therapy faces significant hurdles including immunogenicity and insertional mutagenesis risks.
• A major bottleneck in AAV application is the difficulty in achieving large-scale, high-titer production.

Purpose of the Study:

• To review the current applications of AAV in disease treatment.
• To examine various AAV production methodologies.
• To identify and address challenges related to low viral titers in AAV production and propose solutions.

Main Methods:

• Literature review of AAV gene therapy applications.
• Analysis of existing AAV production platforms and techniques.
• Exploration of strategies to optimize AAV drug production at critical stages.

Main Results:

• AAV vectors are versatile tools for genetic disorders but require careful consideration of safety profiles.
• Current production methods vary, with challenges in scalability and achieving consistent high viral yields.
• Several strategies can be implemented during AAV production to enhance viral titers and overall efficiency.

Conclusions:

• AAV gene therapy holds immense therapeutic potential, but overcoming production limitations is crucial for widespread clinical adoption.
• Addressing immunogenicity and insertional mutagenesis remains paramount for safe and effective AAV treatments.
• Optimizing production processes is key to meeting the demand for high-quality AAV vectors for gene therapy applications.